Background Because clinical characteristics and prognosis vary by geographic region in
patients with heart failure (HF), the response to treatment may also vary. A previous report …

Background Patients with heart failure with reduced ejection fraction (HFrEF) in Asia exhibit
many differences from those in other parts of the world. Objectives This study sought to …

Importance Dapagliflozin was recently shown to reduce cardiovascular death or worsening
heart failure (HF) events in patients with HF with mildly reduced or preserved ejection …

Aims We examined the efficacy and safety of dapagliflozin, compared with placebo,
according to aetiology in patients with heart failure (HF) with reduced ejection fraction …

Background Black people have a higher incidence and prevalence of heart failure (HF) than
White people, and once HF has developed, they may have worse outcomes. There is also …

Importance Additional treatments are needed for heart failure with reduced ejection fraction
(HFrEF). Sodium-glucose cotransporter 2 (SGLT2) inhibitors may be an effective treatment …

Whether the sodium–glucose cotransporter 2 inhibitor dapagliflozin reduces the risk of a
range of morbidity and mortality outcomes in patients with heart failure regardless of ejection …

Objectives This study sought to investigate the efficacy and safety of dapagliflozin in Black
and White patients with heart failure (HF) with reduced ejection fraction (HFrEF) enrolled in …

Aims This pre‐specified analysis of the DELIVER trial examined whether clinical benefits of
dapagliflozin in heart failure (HF) with left ventricular ejection fraction (LVEF)> 40% varied by …

Importance In the Dapagliflozin Evaluation to Improve the Lives of Patients With Preserved
Ejection Fraction Heart Failure (DELIVER) trial, dapagliflozin reduced the risk of time to first …